ArticleActa crystallographica. Section F, Structural biology communications2026
A first structural model for covalent dimerization of S100 proteins.
Article in Acta crystallographica. Section F, Structural biology communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Extracellular S100 proteins act as alarmins and trigger pro-inflammatory signaling cascades by activating cognate cell-surface receptors such as the receptor for advanced glycation end-products (RAGE), thereby contributing to both normal and pathological inflammation depending on the physiological context. These ligand-receptor interactions occur in an oxidative environment that is known to induce post-translational modifications, notably on the cysteine residues present in S100 proteins, giving rise to disulfide-crosslinked S100 species. The fine molecular architecture of these S100 covalent assemblies and their impact on the interaction of S100 with RAGE remains poorly characterized, as most in vitro studies employ cysteine variants or reducing conditions. In this study, a thorough analysis of cysteine conservation within the whole S100 family shows an enriched presence of cysteines in the second half of helix H4, with a hotspot for cysteine occupancy at position 84. Following the introduction of a cysteine at this conserved position in S100A6, SDS-PAGE analysis under nonreducing conditions shows a noteworthy amount of covalent S100A6 Y84C dimer in solution, and the structural analysis of the resulting complex with the RAGE ectodomain reveals the formation of a covalent Cys84-Cys84 linkage between the two S100A6 protomers, thus stabilizing the dimeric conformation of RAGE-bound S100A6. Modeling of other S100 proteins that naturally bear a Cys84 in the RAGE-bound conformation suggests that this covalent S100 dimer architecture may be adopted by other members of the family previously reported to form disulfide-crosslinked species. Altogether, these findings provide a first possible model for S100 covalent homodimerization that is fully compatible with RAGE binding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.